NO2717902T3 - - Google Patents

Info

Publication number
NO2717902T3
NO2717902T3 NO12796397A NO12796397A NO2717902T3 NO 2717902 T3 NO2717902 T3 NO 2717902T3 NO 12796397 A NO12796397 A NO 12796397A NO 12796397 A NO12796397 A NO 12796397A NO 2717902 T3 NO2717902 T3 NO 2717902T3
Authority
NO
Norway
Application number
NO12796397A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2717902(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2717902T3 publication Critical patent/NO2717902T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
NO12796397A 2014-06-20 2012-06-06 NO2717902T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462015245P 2014-06-20 2014-06-20

Publications (1)

Publication Number Publication Date
NO2717902T3 true NO2717902T3 (de) 2018-06-23

Family

ID=53674269

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12796397A NO2717902T3 (de) 2014-06-20 2012-06-06

Country Status (44)

Country Link
US (3) US20170197985A1 (de)
EP (2) EP3157932B1 (de)
JP (4) JP6334007B2 (de)
KR (1) KR101899803B1 (de)
CN (2) CN110563747A (de)
AP (1) AP2016009591A0 (de)
AR (1) AR100903A1 (de)
AU (2) AU2015276860B2 (de)
BR (2) BR122021025861B1 (de)
CA (1) CA2950307C (de)
CL (1) CL2016003249A1 (de)
CR (1) CR20160589A (de)
CU (1) CU24478B1 (de)
CY (1) CY1120025T1 (de)
DK (1) DK3157932T3 (de)
DO (1) DOP2016000327A (de)
EA (2) EA030967B1 (de)
EC (1) ECSP16095566A (de)
ES (1) ES2660862T3 (de)
HR (1) HRP20180455T1 (de)
HU (1) HUE036928T2 (de)
IL (1) IL249161B (de)
LT (1) LT3157932T (de)
MA (2) MA40239B1 (de)
MD (2) MD4584C1 (de)
ME (1) ME03037B (de)
MX (2) MX369555B (de)
MY (1) MY186696A (de)
NO (1) NO2717902T3 (de)
NZ (1) NZ727155A (de)
PE (1) PE20170150A1 (de)
PH (1) PH12016502499A1 (de)
PL (1) PL3157932T3 (de)
PT (1) PT3157932T (de)
RS (1) RS56950B1 (de)
SG (1) SG11201610211QA (de)
SI (1) SI3157932T1 (de)
SV (1) SV2016005339A (de)
TR (1) TR201802179T4 (de)
TW (2) TWI731354B (de)
UA (1) UA118480C2 (de)
UY (1) UY36177A (de)
WO (1) WO2015196116A1 (de)
ZA (1) ZA201608744B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102040007B1 (ko) 2012-12-21 2019-11-05 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (de) * 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
US20180177734A1 (en) * 2015-06-30 2018-06-28 Gilead Sciences, Inc. Pharmaceutical formulations comprising tenofovir and emtricitabine
PL3346995T3 (pl) * 2015-11-09 2020-03-31 Gilead Sciences, Inc. Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3506902A4 (de) * 2016-08-31 2020-04-22 VIIV Healthcare Company Kombinationen und verwendungen und behandlungen davon
EP3518935A1 (de) * 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutische zusammensetzungen zur hemmung des menschlichen immunschwächevirus
CN107445994A (zh) * 2017-05-31 2017-12-08 北京阜康仁生物制药科技有限公司 替诺福韦艾拉酚胺半富马酸盐新晶型
EP3749673B1 (de) * 2018-02-09 2022-03-16 Sandoz AG Kristalline form von bictegravir sodium
WO2019207602A1 (en) 2018-04-26 2019-10-31 Mylan Laboratories Limited Polymorphic forms of bictegravir and its sodium salt
WO2020003151A1 (en) 2018-06-28 2020-01-02 Honour Lab Limited Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form
CN112996517A (zh) * 2018-09-19 2021-06-18 吉利德科学公司 预防hiv的整合酶抑制剂
EP3653629A1 (de) 2018-11-16 2020-05-20 Sandoz AG Säureadditionssalze eines integrase-strangübertragungsinhibitors
WO2020161744A1 (en) 2019-02-07 2020-08-13 Cipla Limited Novel polymorphs of integrase inhibitor
US20220306650A1 (en) * 2019-06-18 2022-09-29 Laurus Labs Limited Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof
CN111978333B (zh) * 2019-09-30 2021-06-18 常州制药厂有限公司 Bictegravir钠盐的晶型A、制备方法及用途
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CN113698420A (zh) * 2020-05-22 2021-11-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型及其制备方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3195799A1 (en) 2020-11-11 2022-05-19 Stephen R. Martin Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
CN112409380A (zh) * 2020-12-10 2021-02-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型的制备方法及其应用
EP4321217A3 (de) 2021-01-19 2024-04-10 Gilead Sciences, Inc. Substituierte pyridotriazinverbindungen und verwendungen davon
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023248240A1 (en) 2022-06-21 2023-12-28 Mylan Laboratories Limited Polymorphic forms of bictegravir sodium
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
DE3900735A1 (de) 1989-01-12 1990-07-26 Hoechst Ag Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
DE4014649A1 (de) 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
AU1403099A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
CN1325385A (zh) 1998-11-09 2001-12-05 詹姆斯·布莱克基金有限公司 胃泌素和缩胆囊素受体配体
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
JP3929244B2 (ja) 1998-12-25 2007-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する芳香族ヘテロ環誘導体
EP1297834A4 (de) 2000-06-14 2007-05-09 Shionogi & Co Enzyminhibitor mit zwei divalenten metallionen als aktiven zentren
KR100977701B1 (ko) 2001-08-10 2010-08-24 시오노기세이야쿠가부시키가이샤 항바이러스제
CZ2004442A3 (cs) 2001-10-03 2005-03-16 Ucb, S.A. Pyrrolidinonové deriváty
CN1700918B (zh) 2001-10-26 2011-06-08 P·安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2004024078A2 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
EP3406596A1 (de) 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxochinolin-verbindung und verwendung davon als hiv-integrasehemmer
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2005074513A2 (en) 2004-01-30 2005-08-18 Merck & Co., Inc. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors
US7619086B2 (en) 2004-03-09 2009-11-17 Merck & Co., Inc. HIV integrase inhibitors
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
EP1755586A2 (de) 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinon-, hydroxypyridinethion-, pyron- und thiopyron-metalloproteinhemmer
ES2529038T3 (es) 2004-05-07 2015-02-16 Merck Sharp & Dohme Corp. Inhibidores de la integrasa de VIH
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP3287130A1 (de) 2004-05-21 2018-02-28 Japan Tobacco Inc. Kombinationen mit einem 4-isochinolon-derivat und proteaseinhibitoren
RS51799B (en) 2004-07-27 2011-12-31 Gilead Sciences Inc. NUCLEOSIDE-PHOSPHONATE CONJUGATES AS HIV AGENTS
US7550463B2 (en) 2004-09-15 2009-06-23 Shionogi & Co., Ltd. Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
JP2006118669A (ja) 2004-10-25 2006-05-11 Sanoh Industrial Co Ltd 樹脂チューブ
EP1973906A1 (de) 2004-12-23 2008-10-01 Virochem Pharma Inc. Hydroxydihydropyridopyrazin-1,8-dione und verfahren zur inhibierung von hiv-integrase
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
MX302718B (es) 2005-04-28 2012-08-27 Smithkline Beecham Corp Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv.
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
WO2007014352A2 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
JP5131689B2 (ja) 2005-10-27 2013-01-30 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
AU2006332664B2 (en) 2005-12-30 2013-03-14 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of HIV integrase inhibitors
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EP1978960A4 (de) 2006-02-01 2009-12-02 Japan Tobacco Inc Verwendung von 6-(3-chlor-2-fluorbenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl[-7-methoxy-4-oxo-1,4-dihydrochinolin-3-carboxylsäure oder einem salz daraus zur behandlung einer retrovireninfektion
US8383819B2 (en) 2006-03-06 2013-02-26 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
CA2661943C (en) 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
AU2007313293A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. HIV integrase inhibitors
NZ579802A (en) 2007-02-23 2012-04-27 Gilead Sciences Inc Compounds for improving the efficacy of other drugs
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
US20110009411A1 (en) 2007-06-29 2011-01-13 Gilead Sciences ,Inc. Therapeutic compositions and the use thereof
AP2965A (en) 2007-06-29 2014-09-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
CA2693340A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2010011813A1 (en) 2008-07-23 2010-01-28 Alkermes, Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2320908B9 (de) 2008-07-25 2014-06-18 VIIV Healthcare Company Prodrugs von Dolutegravir
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2607403T3 (es) 2008-07-25 2017-03-31 Shionogi & Co., Ltd. Compuestos químicos como intermedios sintéticos
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
SG171731A1 (en) 2008-12-11 2011-07-28 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
SG171308A1 (en) 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
RS57244B1 (sr) 2009-06-15 2018-07-31 Shionogi & Co Supstituisani policiklički derivati karbamoilpiridona
WO2011028044A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
RS57323B1 (sr) 2010-01-27 2018-08-31 Viiv Healthcare Co Antivirusna terapija
WO2011105590A1 (ja) 2010-02-26 2011-09-01 日本たばこ産業株式会社 １，３，４，８－テトラヒドロ－２Ｈ－ピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
US9296758B2 (en) 2010-07-02 2016-03-29 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
JP5984218B2 (ja) 2010-07-02 2016-09-06 ギリアード サイエンシーズ， インコーポレイテッド Ａｉｄｓを処置するためのナフト−２−イル酢酸誘導体
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
JP5636054B2 (ja) 2010-08-05 2014-12-03 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する化合物の製造方法
LT2620436T (lt) 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
US9121496B2 (en) 2011-06-29 2015-09-01 Arvinmeritor Technology, Llc Drive axle system and a method of control
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9206197B2 (en) 2011-09-14 2015-12-08 Mapi Pharma Ltd. Amorphous form of dolutegravir
CA2851218A1 (en) 2011-10-12 2013-04-18 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
EP2804864B1 (de) 2011-12-12 2017-09-06 Bayer Intellectual Property GmbH Aminosubstituierte imidazopyridazine
EP2794613B1 (de) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Kondensierte tricyclische verbindungen als hiv-replikations-hemmer
EP3070081B1 (de) 2012-04-20 2018-02-28 Gilead Sciences, Inc. Benzothiazol-6-yl-essigsäure-derivate und deren verwendung zur behandlung einer hiv-infektion
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (de) 2012-07-20 2015-12-23 Merck Sharp & Dohme Hiv-behandlung mit amidosubstituierten pyrimidinonderivaten
US20150218164A1 (en) 2012-07-25 2015-08-06 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
ES2608860T3 (es) 2012-08-03 2017-04-17 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa
MX2015005562A (es) 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa.
PE20151326A1 (es) 2012-12-14 2015-10-12 Glaxosmithkline Llc Composiciones farmaceuticas que comprenden derivados de betulina
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EP2934482A4 (de) 2012-12-21 2016-07-20 Merck Sharp & Dohme Magensaftresistente formulierungen
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
KR102040007B1 (ko) 2012-12-21 2019-11-05 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
JP6320039B2 (ja) 2012-12-27 2018-05-09 日本たばこ産業株式会社 置換されたスピロピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MA38922A3 (fr) 2013-09-27 2018-11-30 Merck Sharp & Dohme Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3096763B1 (de) 2014-01-21 2019-12-25 Laurus Labs Limited Neuartiges verfahren zur herstellung von dolutegravir und pharmazeutisch akzeptablen salzen davon
NO2717902T3 (de) * 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
PL3346995T3 (pl) 2015-11-09 2020-03-31 Gilead Sciences, Inc. Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności

Also Published As

Publication number Publication date
US20160016973A1 (en) 2016-01-21
PE20170150A1 (es) 2017-04-07
WO2015196116A1 (en) 2015-12-23
MD4584B1 (ro) 2018-07-31
SV2016005339A (es) 2017-03-20
MD4584C1 (ro) 2019-02-28
AP2016009591A0 (en) 2016-11-30
ECSP16095566A (es) 2017-01-31
MX369555B (es) 2019-11-12
ZA201608744B (en) 2023-04-26
ES2660862T3 (es) 2018-03-26
US20170197985A1 (en) 2017-07-13
CU20160187A7 (es) 2017-04-05
US20180065986A1 (en) 2018-03-08
CN110563747A (zh) 2019-12-13
LT3157932T (lt) 2018-02-26
TWI731354B (zh) 2021-06-21
AU2015276860A1 (en) 2016-12-22
EP3321270A1 (de) 2018-05-16
AU2015276860B2 (en) 2018-05-31
MY186696A (en) 2021-08-10
MX2016016059A (es) 2017-05-03
SG11201610211QA (en) 2017-01-27
JP2017518356A (ja) 2017-07-06
PT3157932T (pt) 2018-02-21
TWI673274B (zh) 2019-10-01
EA201891464A1 (ru) 2019-03-29
UA118480C2 (uk) 2019-01-25
KR20170016985A (ko) 2017-02-14
HRP20180455T1 (hr) 2018-05-04
IL249161A0 (en) 2017-01-31
BR112016029605A8 (pt) 2021-07-20
MD20170006A2 (ro) 2017-06-30
SI3157932T1 (en) 2018-06-29
BR112016029605A2 (pt) 2017-08-22
PH12016502499B1 (en) 2017-03-22
AU2018203175A1 (en) 2018-05-24
UY36177A (es) 2016-01-08
MA40239A (fr) 2018-01-09
AU2018203175B2 (en) 2020-01-02
CA2950307A1 (en) 2015-12-23
TW201613937A (en) 2016-04-16
CN106459085A (zh) 2017-02-22
CN106459085B (zh) 2019-07-30
JP6334007B2 (ja) 2018-05-30
BR112016029605B1 (pt) 2022-10-11
KR101899803B1 (ko) 2018-09-20
AR100903A1 (es) 2016-11-09
EP3157932A1 (de) 2017-04-26
PL3157932T3 (pl) 2018-05-30
IL249161B (en) 2021-03-25
JP2020097593A (ja) 2020-06-25
MA40239B1 (fr) 2018-05-31
CU24478B1 (es) 2020-03-04
TW202014422A (zh) 2020-04-16
JP2022095640A (ja) 2022-06-28
CR20160589A (es) 2017-02-24
DOP2016000327A (es) 2017-01-15
EP3157932B1 (de) 2018-01-10
PH12016502499A1 (en) 2017-03-22
TR201802179T4 (tr) 2018-03-21
MA44221A (fr) 2018-12-26
CA2950307C (en) 2019-01-08
US10385067B2 (en) 2019-08-20
BR122021025861B1 (pt) 2023-01-24
EA030967B1 (ru) 2018-10-31
MD20180037A2 (ro) 2018-07-31
ME03037B (de) 2018-10-20
CY1120025T1 (el) 2018-12-12
NZ727155A (en) 2022-02-25
RS56950B1 (sr) 2018-05-31
MX2019013380A (es) 2020-02-20
EA201692414A1 (ru) 2017-06-30
CL2016003249A1 (es) 2017-07-14
JP2018162246A (ja) 2018-10-18
DK3157932T3 (en) 2018-03-05
US9708342B2 (en) 2017-07-18
HUE036928T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
BR112014017635A2 (de)
BR112014017614A2 (de)
BR112014017592A2 (de)
BR112014017625A2 (de)
BR112014017659A2 (de)
NO2717902T3 (de)
BR112014017646A2 (de)
BR112014017638A2 (de)
BR112014019369A2 (de)
BR112014018429A2 (de)
BR112014017607A2 (de)
BR112014017634A2 (de)
BR112014017609A2 (de)
BR112014017673A2 (de)
BR112014017644A2 (de)
BR112014017647A2 (de)
BR112014017618A2 (de)
BR112014017652A2 (de)
BR112014017621A2 (de)
BR112014019250A2 (de)
BR112014017630A2 (de)
BR112014017627A2 (de)
BR112014017623A2 (de)
BR112014018659A2 (de)
BR112014017622A2 (de)